CD73 Biomarker Monitoring Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for monitoring disease development and assessing the efficacy of therapies, particularly for conditions like tissue trauma, reperfusion injuries, cancer, and inflammatory conditions, where CD73 levels or activity in tissue fluids are not reliably measured.
Innovation Solution
Measuring soluble CD73 activity in tissue fluids using techniques such as immunodetection or thin layer chromatography to quantify CD73 protein levels or activity, allowing for monitoring of disease severity and treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If CD73 levels are measured in tissue fluids, then disease monitoring and therapy assessment capability is improved, but measurement reliability and precision are insufficient in current methods
Solution Approach 1:
The patent replaces complex mechanical tissue sampling and analysis systems with a simplified biochemical assay system. By measuring soluble CD73 protein levels in tissue fluids (serum, plasma, urine) using enzymatic or immunological methods, the system substitutes invasive mechanical tissue analysis with non-invasive fluid analysis, improving both adaptability and reliability simultaneously
Solution Approach 2:
The patent introduces tissue fluid as an intermediary medium between the disease state and the measurement system. Instead of directly analyzing tissue (which is invasive and complex), the soluble CD73 protein in tissue fluids serves as a measurable intermediary that reflects disease status, enabling reliable and adaptable monitoring without direct tissue manipulation
2Measurement precision
If soluble CD73 activity is measured using immunodetection or thin layer chromatography, then measurement precision is improved, but device complexity and analytical difficulty increase
Solution Approach 1:
The patent changes the measurement parameters from complex tissue-based mechanical analysis to biochemical parameters in fluids. By measuring CD73 protein concentration or enzymatic activity in tissue fluids using standardized biochemical assays (ELISA, TLC), the system achieves high precision while reducing operational complexity to levels accessible in routine clinical laboratories
Solution Approach 2:
The patent employs disposable reagents and standardized assay kits for CD73 measurement, replacing complex, expensive, and maintenance-intensive analytical equipment. The use of commercial ELISA kits, rapid immunochromatographic tests, or standard TLC plates enables precise measurement without requiring sophisticated or costly analytical instrumentation
3Adaptability or versatility
If CD73 is used as a biomarker for monitoring disease development, then therapeutic decision-making is improved, but lack of standardized measurement protocols reduces ease of operation
Solution Approach 1:
The patent establishes soluble CD73 measurement as a universal biomarker applicable across multiple disease states (cancer, inflammation, infection, tissue injury). By developing a single standardized measurement protocol that works for various tissue fluids (serum, plasma, urine, CSF), the system achieves broad therapeutic monitoring utility while maintaining operational simplicity through a universal assay approach
Solution Approach 2:
The patent implements standardized measurement protocols that provide feedback on disease status and therapy response. By establishing reference ranges and interpretive criteria for CD73 levels, the system enables easy operational use in clinical decision-making, allowing practitioners to interpret results without specialized training while maintaining high therapeutic monitoring utility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the monitoring of disease progression and treatment effectiveness by correlating CD73 activity with disease severity and treatment outcomes, facilitating informed therapeutic decisions.
Implementation Method 1
CD73 is a cell-surface enzyme that has 5′-ectonucleotidase activity. It thus mediates the conversion of monophosphorylated purine nucleotides into corresponding nucleosides. For example, dephosphorylation of AMP to adenosine is catalyzed by CD73.
Implementation Method 2
detecting the activity of the CD73 protein in said sample by using thin layer chromatography or by subjecting said sample to a CD73 substrate, and monitoring the change of said substrate
Data Source
AI summary
The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.